TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options for Recurrent ALL
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Recurrent ALL
Treatment options for recurrent acute lymphoblastic leukemia (ALL) include:
Reinduction chemotherapy followed by allogeneic bone marrow transplant (BMT).
Source links and citations
Blinatumomab followed by allogeneic BMT.
Source links and citations
Inotuzumab ozogamicin followed by allogeneic BMT.
Source links and citations
Palliative radiation therapy (for patients with symptomatic recurrence).
Source links and citations
Dasatinib (for patients with Philadelphia chromosome [Ph]–positive ALL).
Source links and citations
Revumenib.
Source links and citations
Patients who do not have an HLA-matched donor are excellent candidates for enrollment in clinical trials that are studying:[1-7]
Patients who do not have an HLA-matched donor are excellent candidates for enrollment in clinical trials that are studying:[1-7]
Autologous transplant.
Patients who do not have an HLA-matched donor are excellent candidates for enrollment in clinical trials that are studying:[1-7]
Immunomodulation.
Patients who do not have an HLA-matched donor are excellent candidates for enrollment in clinical trials that are studying:[1-7]
Chimeric antigen receptor (CAR) T-cell therapy.[8]
Source links and citations
Patients who do not have an HLA-matched donor are excellent candidates for enrollment in clinical trials that are studying:[1-7]
Novel chemotherapeutic or biological agents.
Continue within this section
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice